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for the databases Pubmed, Embase, Biosis, Google Scholar and Cochrane. Data was 
collected for the study size, interventions, year, PRO instrument and results for PROs. 
Analysis for conducted to identify trends in commonly used PRO instruments and 
categorize results as positive, neutral or negative. RESULTS: 31 studies with a total of 
9819 patients were identified. In these studies there were eleven different PROs instru-
ments were identified that were Glaucoma health perception index, Glaucoma quality 
of life questionnaire (Glau-QoL), Glaucoma utility index, Impact of vision impairment, 
Low vision quality of life questionnaire, National eye institute visual function index-
19 items, National eye institute visual function index-51 items, Nursing home vision 
quality of life questionnaire, Quality of life and visual function questionnaire, Vision 
core module 1, and Vision quality of life index. The most commonly used instruments 
were Impact of vision impairment (used in 7 studies) and Low vision quality of life 
questionnaire (used in 4 studies). CONCLUSIONS: Patients with glaucoma have sig-
nificant impairment in their QoL, hence collection of such data is important for new 
medical products. PRO instruments such as Impact of vision impairment and Low 
vision quality of life questionnaire have been commonly used to generate evidence 
to show which therapies improve patient QoL.
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OBJECTIVES: A recent systematic literature review of randomized controlled der-
matology-related trials showed that patient-reported efficacy outcomes (PROs) were 
mentioned in some form in only 25.6% of 125 trials between 1994 and 2001. Our 
research aimed to characterize the benefits of PROs in drug development in derma-
tology from the patient, prescriber, regulator, payer, and manufacturer perspectives 
using a case study approach. The case studies were identified based on the use of 
PROs in pivotal clinical trials for the product. METHODS: A targeted literature review 
was conducted in PubMed from 2004 to 2014 for six products (Atopiclair for atopic 
dermatitis, botulinum toxin type A for hyperhidrosis, calcipotriol plus betametha-
sone dipropionate gel for scalp psoriasis, pimecrolimus and tacrolimus for atopic 
dermatitis, and ustekinumab for psoriasis. Regulatory and health technology agency 
websites and publications were searched for documentation of PRO label claims 
and mentions. RESULTS: For patients, inclusion of PROs ensured the full benefit 
of the product was demonstrated, including improvement in symptoms, quality of 
life, and/or treatment satisfaction. For prescribers, comparative trials reported PRO 
data information on each product’s benefits and risks and also which product was 
superior from the patient perspective. For regulators, for all except one of the six 
products, PROs were included in the product label. For payers, utility values based 
on PROs were used in cost-effectiveness evaluations for three of the six products. 
For the manufacturer, the PRO data generated label claims and many publications 
that allowed extensive public dissemination of product benefits. CONCLUSIONS: 
Patient-reported assessment of the treatment impact on disease during drug devel-
opment has many benefits for all stakeholders.
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OBJECTIVES: A draft patient-reported outcome measure for psoriasis treatment 
(PROMPT) was developed through patient interviews and comprised 91 items 
across seven core domains. This study aimed to evaluate the scaling proper-
ties and construct validity of the draft measure using the Rasch measurement 
model. METHODS: Patients with chronic plaque psoriasis were identified and 
recruited according to pre-defined inclusion and exclusion criteria through pso-
riasis-specific secondary care clinics in the United Kingdom and two national 
patient organizations. Patients completed the draft measure at two time points, 14 
days apart. Respondents with ≥ 40% of missing data were removed from the final 
analyses. Data from each sub-scale were analyzed separately using RUMM2030 
software to explore Rasch model fit, item difficulty, local dependence, item cat-
egory thresholds, and differential item functioning (DIF) by age and gender. Where 
necessary, items were removed individually and the scale iteratively reassessed 
for fit and unidimensionality. RESULTS: A sample of n= 209 patients with chronic 
plaque psoriasis completed the draft measure. Initial fit to the model was poor; 
disordered category thresholds were identified for items in all scales. Post-hocre-
scoring from a 5-point Likert scale to a 3-point Likert scale improved model fit. 
Items which showed local dependence were removed in context of qualitative 
findings. Following removal of 11 items, all 7 scales demonstrated acceptable fit 
with the Rasch model (Chi Sq = 0.09 to 0.2) There was no evidence of DIF by age 
and gender. CONCLUSIONS: The new measure, PROMPT, comprised 80 items in 6 
independent, unidimensional scales, free from age or gender bias, with acceptable 
fit to the Rasch model. As such, the measure is considered to show initial promise 
for use with patients with chronic plaque psoriasis in a clinical setting. The psy-
chometric properties and scoring of the measure should be explored further and 
confirmed in future studies.
PSS35
CONTENT DEVELOPMENT AND REFINEMENT FOR A NEW PATIENT REPORTED 
OUTCOME MEASURE FOR PSORIASIS TREATMENT (PROMPT)
Kitchen H.1, Cordingley L.2, Young H.3, Griffiths C.E.3, Bundy C.2
1Abacus International, Manchester, UK, 2University of Manchester and Manchester Academic 
Health Science Centre, Manchester, UK, 3University of Manchester and Manchester Academic 
Health Science Centre and Salford Royal NHS Foundation Trust, Salford, UK
score distributions and indices of reliability and validity. RESULTS: The literature 
review and input from patients indicates that HS is associated with a range of 
symptoms (e.g., pain, drainage, itchiness) and impacts (e.g., difficulty with move-
ment and interference with sexual activities). These concepts were organized into 
a conceptual model to facilitate the construction of the questionnaires. Results 
from the cognitive interviews indicated that both the HSSA and HSIA are easily 
understood by patients and characterize their condition well. Forty subjects com-
pleted the observational study (females = 58%; Caucasian = 65%; and age [mean] = 
41 years). The HSIA and HSSA scores were found to perform well psychometrically, 
with strong evidence of test-retest (ICC= 0.92 and 0.80, respectively) and internal 
consistency (α = 0.97 and 0.96, respectively) reliability and known groups (P< 0.001 
and P< 0.006, respectively) and construct-related validity (via correlations between 
the target measures and other, concurrently administered tools). CONCLUSIONS: 
There is robust evidence supporting the HSIA and HSSA as content valid and 
psychometrically sound questionnaires for assessing symptoms and impacts in 
patients with HS.
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OBJECTIVES: Visual acuity does not fully capture the effect of geographic atro-
phy (GA), secondary to age-related macular degeneration, on visual function. The 
Functional Reading Independence (FRI) Index is a 7-item patient-reported measure 
developed for use in GA trials. This study examined the sensitivity of the FRI Index 
to change in GA lesion size. METHODS: Post hoc analyses were conducted with data 
from MAHALO, a phase 2 study of lampalizumab, a complement factor monoclonal 
antibody fragment, for treatment of GA. For each reading activity performed in the 
past 7 days (e.g., writing checks or reading medicine labels), patients were asked the 
extent to which they required vision aids, adjustments in the activity, or help from 
another person. The FRI Index yields continuous mean scores (range 1-4) and ordinal 
level scores (from Level 1= Unable to do to Level 4= Totally Independent). Analysis 
of covariance compared mean changes in FRI Index scores stratified by more 
(≥ 0.94mm2/yr) vs less (< 0.94mm2/yr) GA lesion growth. RESULTS: At 18 months, the 
mean change in FRI Index score (SD) from baseline for patients with more lesion size 
growth was -0.3 (0.5; n= 13) vs -0.1 (0.7; n= 62) for patients with less growth (P= 0.02). 
For patients with more growth, 36% declined ≥ 1 FRI Level vs 15% for less growth. 
Excluding patients at FRI Level 1 at baseline, 41% of patients with more growth 
(N= 54) declined > 1 FRI Level vs 18% with less growth (N= 11). CONCLUSIONS: In 
MAHALO, the change in mean FRI Index score of 0.2 differentiated patients with 
more vs less growth of GA lesion size. FRI level scores were also sensitive to GA 
lesion growth. These results provide evidence that patient-reported functional read-
ing independence as measured by the FRI Index is linked to GA lesion growth, an 
objective clinical measure of disease progression.
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OBJECTIVES: Translation and linguistic validation of patient reported outcomes (PRO) 
measures is an essential component of research methodology in preparation for mul-
tinational research studies. The Urticaria Activity and Impact Measure (U-AIM) is a dis-
ease specific tool developed in English to assess the impact of chronic urticaria from 
the patient’s viewpoint. The objective of this work was to translate and linguistically 
validate the U-AIM from English to Spanish for use in the US. METHODS: The U-AIM 
was translated into universal Spanish according to industry standard methodology. 
After the translation was completed, five Spanish-speaking patients in the US diag-
nosed with chronic idiopathic urticaria completed the translated questionnaire and 
participated in a cognitive debriefing interview. Interviews were conducted using a 
standardized guide to assess the relevance, understandability, and appropriateness of 
the translations. Qualitative analyses were performed to ensure equivalence and that 
the content validity of the U-AIM was maintained for the Spanish version. RESULTS: 
Of the five patients (40% male), the mean age of four was 37 years [one patient did 
not report his age]. All U-AIM items were well understood and proved relevant to the 
patients in this sample. Of interest, terms such as, “urticaria,” “hives,” “angioedema” 
and “rapid swelling” were clearly understood as intended. CONCLUSIONS: The results 
indicate that the Spanish version of the U-AIM translation is conceptually equivalent 
to the English source version and easily understood by the target population in the US. 
We consider the translation to be acceptable for PRO assessment in research and clini-
cal practice. Future research could include testing of the questionnaire with patients 
in other Spanish-speaking countries to confirm its acceptability beyond the US.
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OBJECTIVES: Patient reported outcomes (PRO) are becoming useful tools for collecting 
and generating evidence for new medical products to show improvements in health-
related quality of life (HRQoL). Glaucoma is a chronic disease with high importance 
for patient HRQoL. The objective of this study was to review, analyze, and understand 
trends in the PRO instruments used in patients with Glaucoma. METHODS: A sys-
tematic literature search for Glaucoma trials with PROs endpoints was undertaken 
